Ensysce Biosciences And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

Benzinga

Published Mar 07, 2023 11:53

Updated Mar 07, 2023 13:10

Ensysce Biosciences And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

Benzinga - The Dow Jones rose around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

h2 Ensysce Biosciences /h2
  • The Trade: Ensysce Biosciences, Inc. (NASDAQ: ENSC) Director Bob G Gower bought a total of 90,287 shares at an average price of $0.49. To acquire these shares, it cost around $44.09 thousand.
  • What’s Happening: Ensysce Biosciences announced critical step in human abuse potential study of PF614 with database lock.
  • What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.
h2 Global Clean Energy Holdings /h2
  • The Trade: Global Clean Energy Holdings, Inc. (OTC: GCEH) 10% owner Michael Zilkha acquired a total 141,020 shares at an average price of $0.56. The insider spent around $78.97 thousand to buy those shares.
  • What’s Happening: The company’s stock tumbled 57% over the past six months.
  • What Global Clean Energy Holdings Does: Global Clean Energy Holdings Inc is a United States-based energy agri-business focused on the development of ultra-low carbon non-food based feedstocks for renewable fuels and chemicals in the US, Mexico, and the Caribbean.
Check This Out: Top 4 Real Estate Stocks That That May Plunge

h2 Castellum/h2
  • The Trade: Castellum, Inc. (NYSE: CTM) 10% owner Jay Wright acquired a total of 30,100 shares at an average price of $1.00. To acquire these shares, it cost around $29.98 thousand.
  • What’s Happening: Castellum recently reported a $500,000 Equity financing.
  • What Castellum Does: Castellum Inc, formerly BioNovelus Inc is engaged in acquiring and growing technology companies in the areas of information technology and cybersecurity with businesses in the public (government) and private (commercial) markets.
Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes